Cantor Fitzgerald analyst Elemer Piros initiated after the close yesterday shares of Intercept Pharmaceuticals (ICPT) with a Sell rating and $58 price target. The stock closed yesterday down 62c to $142.85. The analyst is "unenthusiastic" about Ocaliva's future in nonalcoholic steatohepatitis. He identified six areas of weaknesses in the previous clinical package and the design of the currently ongoing Phase III trial. Piros last night also initiated shares of Tobira Therapeutics (TBRA) with a Buy rating and $27 price target. The company could become a leading contender for the treatment of nonalcoholic steatohepatitis following its data release in Q3, the analyst told investors in a research note.